This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sigma Labs, Inc. Signs Licensing Agreement With Allotrope Sciences Relating To Reactive Munitions Technologies

Stocks in this article: SGLB

SANTA FE, N.M., April 10, 2013 /PRNewswire/ -- Sigma Labs, Inc. (OTCBB: SGLB) announced today that it has signed a licensing agreement with Allotrope Sciences, Corp. to market and commercialize Sigma Labs innovative reactive munitions technologies – ARMS and BAM. Terms were not disclosed. 

Bonded Advanced Materials ("BAM") and Advanced Reactive Materials and Structures ("ARMS") are projectile and munitions-related technologies developed by Sigma Labs, and have wide applicability for use on new weapons systems.   

Allotrope was founded by and Alan Yarborough and Dr. Robert Phillips specifically established for the commercialization of innovative defense related technologies.  The founders have significant previous success in selling novel technologies to military and defense customers, such as U.S. Government clients.  

Mark Cola, President and Chief Executive Officer of Sigma Labs, stated that "Allotrope is precisely the type of commercialization partner we seek: Allotrope's management has a proven track record in selling to government clients and also has significant experience with munitions and military technology. They also have the ability to follow through on a well-developed business plan that involves further product development as well as marketing and sales."  Alan Yarborough, Chief Executive Officer of Allotrope, stated that "Both through my direct military service as well as my support roles in counter-terrorism, force transformation, counter-IED, etc., I have a thorough appreciation of what is required to market Sigma's munitions  technology to the military sector.  I am very optimistic about the potential of Sigma Labs' unique technology offerings and will immediately commence an aggressive plan of commercialization which we have organized to serve U.S. military and allied interests globally."  

Mark Cola, President and Chief Executive Officer of Sigma, added that "As part of our strategy to monetize our IP and realize significant revenue growth within the 2013-2014 timeframe, this agreement considerably advances the commercialization of our munitions technologies.   Further, this agreement allows Sigma Labs to continue its' focus on other technical areas such as Additive Manufacturing and 3D printing, where we have focused the majority of our effort at this time."

About Sigma Labs, Inc. Sigma Labs, Inc. has three wholly-owned subsidiaries – B6 Sigma, Inc., Sumner & Lawrence Limited (dba Sumner Associates) and La Mancha Company. B6 Sigma develops advanced manufacturing solutions and materials technologies, as well as R&D solutions for first-tier integrators and other commercial firms worldwide.  Sumner Associates and La Mancha provide high-level consultants to Federal government and commercial clients seeking productive solutions for emerging and strategic development technologies.  Sigma Labs has current contracts with Federal government and private industry clients to provide high-level consultants and develop technologies from their conception through the design, building, and testing of prototype systems.  For more information please visit us at  www.sigmalabsinc.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 Forward-looking statements often contain words such as "expects," "anticipates," "intends," "believes" or "will." Our forward-looking statements are subject to a number of risks, uncertainties and assumptions that could adversely affect us, including the risks set forth in our most recent annual report on Form 10-K. The forward-looking statements in this press release are made only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Sigma Labs, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs